Skip to main content

Advertisement

Table 1 Baseline patient characteristics

From: A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]

Characteristic Placebo Etoricoxib 90 mg Naproxen 1000 mg
  (N = 357) (N = 353) (N = 181)
% women 82 81 82
Mean age [yrs] (SD) 52 (12) 53 (12) 52 (12)
Mean duration of rheumatoid arthritis [yrs] (SD) 9 (8) 8 (8) 8 (8)
% rheumatoid factor-positive 83 85 87
% in ARA functional class:    
   I 27 31 27
   II 56 53 58
   III 17 16 16
% taking rheumatoid arthritis medications:    
   Corticosteroids 57 54 59
   Disease modifying antirheumatic drugs 83 83 81
   Methotrexate 59 55 62
Mean patient global assessment of disease activity (100 mm visual analog scale) (SD) 65 (19) 66 (20) 65 (19)
Mean investigator global assessment of disease activity (0 to 4 scale) (SD) 2.7 (0.6) 2.7 (0.7) 2.7 (0.6)
Mean number of tender joints (of 68) (SD) 29 (15) 29 (15) 28 (15)
Mean number of swollen joints (of 66) (SD) 19 (12) 19 (13) 18 (12)
  1. Higher score corresponds to greater disease activity.